Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.

@article{Fisher2011ObservationPT,
  title={Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.},
  author={Rosalie Anne Fisher and Alexandra Pender and Kiruthikah Thillai and Simon Chowdhury and Lisa M. Pickering and Suzanne St.Rose and MartinE. Gore and James Michael Larkin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4630}
}
4630 Background: Patients with metastatic renal cell carcinoma (mRCC) are heterogenous, with significant variation in clinical course. The use of vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) kinase inhibitors has dramatically changed the prognosis for these patients. However, these treatments are non-curative, necessitating chronic therapy. There is a cohort of patients with indolent disease in whom the initiation of systemic therapy is often… CONTINUE READING
BETA

Similar Papers

Loading similar papers…